2. Disease Areas
  3. Inflammation or Immune System Disease
  4. Pathogens Infection
  5. Rhinosinusitis

Rhinosinusitis

Rhinosinusitis refers to the inflammation of the nasal and sinus mucosa, commonly presenting with symptoms like nasal congestion, rhinorrhea, facial pain or pressure, and reduced sense of smell. It can be classified as acute, subacute, or chronic based on duration, and further categorized by etiology including infectious (viral, bacterial), allergic, nonallergic, or mixed forms. The condition often results from obstruction, infection, or hypersensitivity, leading to impaired sinus drainage and persistent inflammation.

Rhinosinusitis (1):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P990774
    Verekitug 2768386-15-6
    Verekitug (ASP-7266; TRAB-1; UPB-101) is a human monoclonal antibody targeting the thymic stromal lymphopoietin receptor (TSLPR), with a mean half-life of approximately 20 days. At doses of Verekitug ≥100 mg, complete and sustained TSLPR-specific occupancy is achieved, and the antibody does not bind to IL-7Rα. By inhibiting TSLP-driven inflammatory responses, Verekitug blocks TSLP-induced cell proliferation and TARC expression, while reducing fractional exhaled NO levels, blood eosinophil counts, and levels of IL-5 and IgE. Verekitug significantly improves scores for nasal polyps, nasal congestion and olfactory dysfunction, with favorable safety and good tolerability; potential adverse reactions include headache, upper respiratory tract infection, sinusitis and nasopharyngitis. Verekitug is used in relevant studies on asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
    Verekitug